|
INN name:
|
Entrectinib
|
||||||
|
Lab codes:
|
RXDX-101
|
||||||
|
Chemical name:
|
N-{5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl}-4-(4-methylpiperazin-1-yl)-2-[(oxan-4-yl)amino]benzamide
| ||||||
Molecular formula:
|
C31H34F2N6O2
|
||||||
|
Chemical Structure:
|
 |
||||||
|
CAS Registry Number:
|
1108743-60-7
|
||||||
|
Originator:
|
Nerviano
Medical Sciences
|
||||||
|
Developer:
|
Ignyta;
Nerviano Medical Sciences
| ||||||
Class:
|
Antineoplastics
|
||||||
|
Mechanism of Action:
|
Anaplastic
lymphoma kinase inhibitors; ROS1-protein-inhibitors; TrkA receptor antagonists;
TrkB receptor antagonists; TrkC receptor antagonists
|
||||||
|
WHO ATC code:
|
L01X-E
(Protein kinase inhibitors)
| ||||||
EPhMRA code:
|
L1H
(Protein Kinase Inhibitor Antineoplastics)
|
||||||
|
Clinical Trials:
|
|||||||
|
Product Patent
Expiry:
For patent data
contact us at drugpatentexpiry@gmail.com
|
|||||||
Friday, 18 September 2015
Entrectinib
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment